Laromestrocel is the international nonproprietary name (INN) for Longeveron's cellular therapy Lomecel-B. It is an allogeneic medicinal signaling cell product in clinical-stage development for hypoplastic left heart syndrome, Alzheimer's disease, and aging-related frailty. The product remains investigational.
Longeveron Inc. announced Phase 2b clinical trial results published in Cell Stem Cell showing laromestrocel improved physical condition in patients with age-related frailty after nine months compared to placebo.
Longeveron Inc. appointed Stephen H. Willard as CEO effective February 11, 2026, replacing interim CEO Than Powell. The appointment comes as the company expects top-line results from its pivotal Phase 2b trial for Hypoplastic Left Heart Syndrome in Q3 2026.
